Plasma is a biofluid widely used for biomarker discovery. The plasma proteome is a circulating snapshot of the body’s (patho)physiological state, however, potential biomarkers can be ‘buried’ beneath abundant plasma proteins, the top 20 comprising ~99% of plasma proteome.
Plasma proteomics must balance proteome depth with high-throughput capabilities for analysing 100s-1000s patients. Furthermore, any method which fractionates, subsets or depletes cannot compromise quantitation or risk eliminating benefits of increasing proteome depth.
Partnering with collaborators at Murdoch Children’s Research Institute, this project will:
- optimise new methods for improved plasma proteomics
- validate methods in clinical cohorts.
Opportunities exist to learn advanced proteomics workflows, including hands-on experience with mass spectrometry instrumentation. Further, this project will liaise with clinical collaborators, focusing on pediatric health, pathologies and development.